ARS defines anatomy-based hypofractionation strategies for stage III NSCLC without concurrent chemotherapy

New ARS consensus supports 60 Gy in 15 fractions for selected peripheral tumors but recommends more conservative schedules near critical structures.

KEY POINTS

  • The American Radium Society (ARS) Thoracic Appropriate Use Criteria Panel, comprising 15 multidisciplinary experts, evaluated accelerated hypofractionated RT for unresectable stage III NSCLC in patients ineligible for concurrent chemotherapy. A systematic literature review identified 14 relevant prospective trials or registries from 228 publications, including nine phase I–II trials, four registries and one randomized phase III trial; recommendations were developed through a modified Delphi process across five anatomical scenarios.
  • For favorable peripheral stage IIIA disease without proximity to the heart, esophagus or brachial plexus, the panel considered 60 Gy in 15 fractions usually appropriate when delivered with conformal techniques. 50–55.5 Gy in 15 fractions might be appropriate when technical or anatomical limitations prevent higher-dose treatment, whereas 45 Gy in 15 fractions was considered generally insufficient for definitive treatment in otherwise favorable anatomy.
  • For tumors abutting the heart, the panel favored IMRT or proton therapy to minimize cardiac exposure and considered 45–55 Gy in 15 fractions potentially appropriate, without consensus supporting 60 Gy in 15 fractions. For mediastinal nodal disease directly adjacent to the esophagus, 50–55.5 Gy in 15 fractions might be appropriate, while escalation beyond 55.5 Gy in 15 fractions was discouraged because of the risk of severe esophageal injury.
  • In patients with bulky T4/N3 disease or supraclavicular nodes adjacent to the brachial plexus, the panel considered 60 Gy in 15 fractions inappropriate because of cardiopulmonary, esophageal or neurologic toxicity risk. More protracted regimens, particularly 55–60 Gy in 20 fractions or 60 Gy in 30 fractions, remained appropriate across the clinical variants, emphasizing that accelerated hypofractionation is not obligatory.
  • Modern conformal techniques were consistently preferred. IMRT and proton therapy were considered appropriate across the five scenarios, while 3D conformal RT was generally discouraged except in favorable anatomy. The panel proposed aiming for lung V20Gy <30%, heart V40Gy <20%, esophageal maximum dose <55 Gy and brachial plexus maximum dose <50 Gy, while acknowledging that these are consensus objectives rather than universally validated constraints for every hypofractionated schedule.
  • Regarding systemic therapy sequencing, the panel considered consolidative PD-L1-directed immunotherapy after definitive RT appropriate for selected patients, extrapolating from existing immunotherapy evidence. Concurrent immunotherapy was considered inappropriate, while induction immunotherapy might be appropriate in selected bulky or N3 presentations to assess disease biology; importantly, direct randomized evidence supporting these sequences in chemotherapy-ineligible patients remains limited.
  • The panel emphasized that 60 Gy in 30 fractions remains appropriate because accelerated hypofractionation has not demonstrated superiority in randomized trials. The available randomized evidence included concerns about increased grade ≥2 toxicity without clear oncological benefit, reinforcing the need to balance disease burden, treatment duration, organ-at-risk proximity, comorbidities and expected quality of life.

CLINICAL TAKEAWAY

For stage III NSCLC patients unable to receive concurrent chemotherapy, accelerated hypofractionation should be selected according to tumor anatomy rather than applied uniformly. The ARS framework supports 60 Gy in 15 fractions for favorable peripheral disease, favors more conservative schedules near critical structures, and retains conventional fractionation as a valid option; these are evidence-informed consensus recommendations, not proof that accelerated treatment improves survival.

SOURCE

International Journal of Radiation Oncology, Biology, Physics

Browse more research Suggest a correction